Detalhe da pesquisa
1.
4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.
Bioorg Med Chem Lett
; 20(20): 6096-9, 2010 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20817449
2.
Characterization of the CHK1 allosteric inhibitor binding site.
Biochemistry
; 48(41): 9823-30, 2009 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-19743875
3.
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
J Med Chem
; 59(5): 2005-24, 2016 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26756222
4.
Effects of Activating Mutations on EGFR Cellular Protein Turnover and Amino Acid Recycling Determined Using SILAC Mass Spectrometry.
Int J Cell Biol
; 2015: 798936, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26689952